ADIL: רווח למניה בשנים עשר החודשים האחרונים Adial Pharmaceuticals Inc.

Adial Pharmaceuticals is developing a comprehensive addiction treatment system by integrating the drug AD04 into psychiatric practice. The 12-month net income per share trend illustrates the business recovery process, where the -16.62 mark reflects the current state. The current budget relies exclusively on investor capital due to a lack of sales, while market positions are protected from direct dumping by patents.

Adial Pharmaceuticals' personalized approach to addiction therapy directly impacts the future monetization of genetic tests. This indicator reflects the portion of net income attributable to a single common share over a rolling year. The metric allows for an assessment of the actual efficiency of business scaling by excluding the influence of the total volume of issuance. For the investor, this serves as a tool for analyzing return on capital amid regulatory risks. The trend in the rolling net income per share visualizes the pace at which the company's fundamental successes are being capitalized.